Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Hodgkin Lymphoma.

The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).

This statement is based on a regulatory approval from the European Medicines Agency:

ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).

Citation

Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised March 2026. Accessed August 2, 2026.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2016-06-24	European Medicines Agency	Indication received approval from the European Commission.